NEW YORK, Feb. 21, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Stemline Therapeutics, Inc. (“Stemline”) (NASDAQ:STML) (1) pursuant and/or traceable to Stemline's secondary public offering on or about January 20, 2017; and/or (2) on the open market between January 6, 2017 and February 1, 2017, inclusive. You are hereby notified that Levi & Korsinsky has commenced the class action Braswell v. Stemline Therapeutics, et al. (Case No. 1:17-cv-00853) in the USDC for the Southern District of New York. Click here to view the complaint. To get more information go to:
http://www.zlk.com/pslra/stemline-therapeutics
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the class period the Company made materially false and/or misleading statements and/or failed to disclose that: (i) a patient had died in the BPDCN Trial from capillary leak syndrome immediately prior to the Company’s stock offering despite consistently stating that capillary leak syndrome was a potential side-effect of SL-401; and (ii) SL-401’s safety profile did not remain predictable and manageable over increasing treatment duration, drug exposure, and patient experience as represented by the Defendants.
Take Action: if you suffered a loss in Stemline Therapeutics you have until April 4, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Chinese Cars in Europe: Consumer Trust Is Shifting Fast
OpenAI Addresses Security Vulnerability in macOS App Certification Process
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 



